SHP2's gain‐of‐function in Werner syndrome causes childhood disease onset likely resulting from negative genetic interaction

Prompt diagnosis of complex phenotypes is a challenging task in clinical genetics. Whole exome sequencing has proved to be effective in solving such conditions. Here, we report on an unpredictable presentation of Werner Syndrome (WRNS) in a 12‐year‐old girl carrying a homozygous truncating variant in RECQL2, the gene mutated in WRNS, and a de novo activating missense change in PTPN11, the major Noonan syndrome gene, encoding SHP2, a protein tyrosine phosphatase positively controlling RAS function and MAPK signaling, which have tightly been associated with senescence in primary cells. All the major WRNS clinical criteria were present with an extreme precocious onset and were associated with mild intellectual disability, severe growth retardation and facial dysmorphism. Compared to primary fibroblasts from adult subjects with WRNS, proband's fibroblasts showed a dramatically reduced proliferation rate and competence, and a more accelerated senescence, in line with the anticipated WRNS features occurring in the child. In vitro functional characterization of the SHP2 mutant documented its hyperactive behavior and a significantly enhanced activation of the MAPK pathway. Based on the functional interaction of WRN and MAPK signaling in processes relevant to replicative senescence, these findings disclose a unique phenotype likely resulting from negative genetic interaction.

[1]  Jenny J. Li,et al.  Expression of oncogenic HRAS in human Rh28 and RMS-YM rhabdomyosarcoma cells leads to oncogene-induced senescence , 2021, Scientific Reports.

[2]  R. Hennekam Pathophysiology of premature aging characteristics in Mendelian progeroid disorders. , 2020, European journal of medical genetics.

[3]  C. Vigouroux,et al.  Overlapping phenotypes between SHORT and Noonan syndromes in patients with PTPN11 pathogenic variants , 2020, Clinical genetics.

[4]  E. Shagimardanova,et al.  PTPN11 Knockdown Prevents Changes in the Expression of Genes Controlling Cell Cycle, Chemotherapy Resistance, and Oncogene-Induced Senescence in Human Thyroid Cells Overexpressing BRAF V600E Oncogenic Protein , 2020, Biochemistry (Moscow).

[5]  M. Rooman,et al.  Digenic inheritance of human primary microcephaly delineates centrosomal and non‐centrosomal pathways , 2019, Human mutation.

[6]  Ben Lehner,et al.  The impact of nonsense-mediated mRNA decay on genetic disease, gene editing and cancer immunotherapy , 2019, Nature Genetics.

[7]  A. Rehman,et al.  The Landscape of Protein Tyrosine Phosphatase (Shp2) and Cancer. , 2019, Current pharmaceutical design.

[8]  A. Asaithamby,et al.  Werner Syndrome Protein and DNA Replication , 2018, International journal of molecular sciences.

[9]  J. Cruysberg,et al.  Ocular findings in Noonan syndrome: a retrospective cohort study of 105 patients , 2018, European Journal of Pediatrics.

[10]  J. Li,et al.  Plk1 Phosphorylation of Mre11 Antagonizes the DNA Damage Response. , 2017, Cancer research.

[11]  Monia Magliozzi,et al.  Structural, Functional, and Clinical Characterization of a Novel PTPN11 Mutation Cluster Underlying Noonan Syndrome , 2017, Human mutation.

[12]  Donna M. Muzny,et al.  Resolution of Disease Phenotypes Resulting from Multilocus Genomic Variation , 2017, The New England journal of medicine.

[13]  M. Poot,et al.  WRN Mutation Update: Mutation Spectrum, Patient Registries, and Translational Prospects , 2017, Human mutation.

[14]  B. Neel,et al.  Gain-of-function mutations of Ptpn11 (Shp2) cause aberrant mitosis and increase susceptibility to DNA damage-induced malignancies , 2016, Proceedings of the National Academy of Sciences.

[15]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[16]  F. d’Adda di Fagagna,et al.  Stable Cellular Senescence Is Associated with Persistent DDR Activation , 2014, PloS one.

[17]  V. Bohr,et al.  Human RecQ helicases in DNA repair, recombination, and replication. , 2014, Annual review of biochemistry.

[18]  C. Myers,et al.  Genetic interaction networks: toward an understanding of heritability. , 2013, Annual review of genomics and human genetics.

[19]  B. Donadille,et al.  Partial lipodystrophy with severe insulin resistance and adult progeria Werner syndrome , 2013, Orphanet Journal of Rare Diseases.

[20]  T. Miki,et al.  Diagnostic criteria for Werner syndrome based on Japanese nationwide epidemiological survey , 2013, Geriatrics & gerontology international.

[21]  R. Monnat,et al.  Spectrum and Risk of Neoplasia in Werner Syndrome: A Systematic Review , 2013, PloS one.

[22]  Y. Ishikawa,et al.  Werner syndrome: a changing pattern of clinical manifestations in Japan (1917~2008). , 2013, Bioscience trends.

[23]  M. Bignami,et al.  The Werner syndrome protein: linking the replication checkpoint response to genome stability , 2011, Aging.

[24]  B. Gelb,et al.  Noonan syndrome and clinically related disorders. , 2011, Best practice & research. Clinical endocrinology & metabolism.

[25]  M. Bignami,et al.  ATR and ATM differently regulate WRN to prevent DSBs at stalled replication forks and promote replication fork recovery , 2010, The EMBO journal.

[26]  V. Bohr,et al.  Roles of Werner syndrome protein in protection of genome integrity. , 2010, DNA repair.

[27]  T. Hakoshima,et al.  Structural basis for DNA strand separation by the unconventional winged-helix domain of RecQ helicase WRN. , 2010, Structure.

[28]  J. Chambard,et al.  ERK and cell death: Mechanisms of ERK‐induced cell death – apoptosis, autophagy and senescence , 2010, The FEBS journal.

[29]  S. Carr,et al.  A Mitotic Phosphorylation Feedback Network Connects Cdk1, Plk1, 53BP1, and Chk2 to Inactivate the G2/M DNA Damage Checkpoint , 2010, PLoS biology.

[30]  Lye Mun Tho,et al.  The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. , 2010, Advances in cancer research.

[31]  T. Matozaki,et al.  Protein tyrosine phosphatase SHP‐2: A proto‐oncogene product that promotes Ras activation , 2009, Cancer science.

[32]  K. Kawakami,et al.  Expression of H-RASV12 in a zebrafish model of Costello syndrome causes cellular senescence in adult proliferating cells , 2009, Disease Models & Mechanisms.

[33]  B. Neel,et al.  The tyrosine phosphatase Shp2 (PTPN11) in cancer , 2008, Cancer and Metastasis Reviews.

[34]  Markus Schuelke,et al.  The spectrum of WRN mutations in Werner syndrome patients , 2006, Human mutation.

[35]  R. Foà,et al.  Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. , 2006, American journal of human genetics.

[36]  X. Xi,et al.  Solution structure of a multifunctional DNA- and protein-binding motif of human Werner syndrome protein. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[37]  R. Verdun,et al.  Defective Telomere Lagging Strand Synthesis in Cells Lacking WRN Helicase Activity , 2004, Science.

[38]  M. Loh,et al.  SHP-2 and myeloid malignancies. , 2004, Current opinion in hematology.

[39]  F. Rosselli,et al.  Werner's syndrome protein is phosphorylated in an ATR/ATM-dependent manner following replication arrest and DNA damage induced during the S phase of the cell cycle , 2003, Oncogene.

[40]  M. Emond,et al.  Homologous Recombination Resolution Defect in Werner Syndrome , 2002, Molecular and Cellular Biology.

[41]  M. Poot,et al.  Werner syndrome diploid fibroblasts are sensitive to 4‐nitroquinoline‐N‐oxide and 8‐methoxypsoralen: implications for the disease phenotype , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[42]  J. Oshima,et al.  Werner Syndrome , 2020, Constitutional Oncogenetics.

[43]  Michael A. Patton,et al.  Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome , 2001, Nature Genetics.

[44]  P. Mosesso,et al.  Werner's syndrome protein is required for correct recovery after replication arrest and DNA damage induced in S-phase of cell cycle. , 2001, Molecular biology of the cell.

[45]  I. Saira Mian,et al.  The premature ageing syndrome protein, WRN, is a 3′→5′ exonuclease , 1998, Nature Genetics.

[46]  S. Shoelson,et al.  Crystal Structure of the Tyrosine Phosphatase SHP-2 , 1998, Cell.

[47]  M. Gray,et al.  The Werner syndrome protein is a DNA helicase , 1997, Nature Genetics.

[48]  G. Schellenberg,et al.  Positional Cloning of the Werner's Syndrome Gene , 1996, Science.